FDA Grants Priority Review to Capmatinib for Non-Small Cell Lung Cancer

The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.

Source: CancerNetwork - February 11, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news